This inventor holds 8 USPTO granted patents and 4 EPO patents. Top assignees: Arcturus Therapeutics, Inc., Marina Biotech, Inc., Other. Active years: 2012-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Odense C, DK (2012 - 2019)
- Langeskov, DK (2020 - 2022)
Company Filing History:
6 out of 65 
1 out of 25 
1 out of 834,570 Years Active: 2012-2022
Title: Jesper Wengel: Innovator in Therapeutic Methods
Introduction
Jesper Wengel is a prominent inventor based in Odense C, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic methods for genetic diseases. With a total of eight patents to his name, Wengel's work focuses on innovative solutions for complex medical challenges.
Latest Patents
One of Wengel's latest patents is a therapeutic method for Huntington's disease. This invention involves anti-gene oligonucleotides designed to hybridize to DNA in the HTT gene. These oligonucleotides are based on locked nucleic acids and phosphorodiamidate morpholino oligomers. They target sequences where the majority of repeats are CAG/CTG, aiming to down-regulate the expression of the HTT gene. This results in reduced HTT mRNA and protein levels in affected individuals, contributing to the diagnosis, treatment, and prevention of Huntington's disease. Additionally, the invention includes a delivery system for these oligonucleotides, which can target non-canonical DNA structures.
Another notable patent involves acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides. This patent describes a single-stranded oligonucleotide containing two or more acyl-amino-LNA or hydrocarbyl-amino-LNA nucleotide monomers, which can be combined with other nucleotide types such as DNA or RNA.
Career Highlights
Throughout his career, Jesper Wengel has worked with several notable companies, including Arcturus Therapeutics, Inc. and Marina Biotech, Inc. His expertise in oligonucleotide technology has positioned him as a leader in the field of therapeutic innovations.
Collaborations
Wengel has collaborated with various professionals in his field, including Rula Zain-Luqman and C I Edvard Smith. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Jesper Wengel's innovative work in therapeutic methods showcases his commitment to addressing significant medical challenges. His contributions to biotechnology, particularly in the context of Huntington's disease, highlight the importance of continued research and development in this vital area.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile